InnoCan Pharma (FRA:IP40) Retained Earnings: €-32.01 Mil (As of Mar. 2026)


FRA:IP40 InnoCan Pharma Corp FRA:IP40
54 GF Score
Price €1.92
GF Value €8.36
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is InnoCan Pharma Retained Earnings?

InnoCan Pharma FRA:IP40 -1.54% 54 Retained Earnings is €-32.01 Mil as of Mar. 2026. GuruFocus rates FRA:IP40 with a GF Score™ of 54/100 and a GF Value™ of €8.36 (Possible Value Trap). The stock has 2 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. InnoCan Pharma's retained earnings for the quarter that ended in Mar. 2026 was €-32.01 Mil.

InnoCan Pharma's quarterly retained earnings increased from Sep. 2025 (€-32.40 Mil) to Dec. 2025 (€-30.77 Mil) but then declined from Dec. 2025 (€-30.77 Mil) to Mar. 2026 (€-32.01 Mil).

InnoCan Pharma's annual retained earnings declined from Dec. 2023 (€-30.33 Mil) to Dec. 2024 (€-33.34 Mil) but then increased from Dec. 2024 (€-33.34 Mil) to Dec. 2025 (€-30.77 Mil).


InnoCan Pharma  (FRA:IP40) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


InnoCan Pharma Retained Earnings Historical Data

* Premium members only.

The historical data trend for InnoCan Pharma's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InnoCan Pharma Retained Earnings Chart

InnoCan Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial -21.78 -26.79 -30.33 -33.34 -30.77

InnoCan Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -32.83 -31.28 -32.40 -30.77 -32.01
FRA:IP40
54GF Score
InnoCan Pharma Corp FRA:IP40
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InnoCan Pharma Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of €-32.01 Mil mean?
InnoCan Pharma (FRA:IP40) has a Retained Earnings of €-32.01 Mil as of Mar. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on InnoCan Pharma and its competitors.
Is InnoCan Pharma's Retained Earnings too high?
InnoCan Pharma's current Retained Earnings is €-32.01 Mil. Overall, InnoCan Pharma has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InnoCan Pharma's Retained Earnings compare to PG and CL?
InnoCan Pharma's Retained Earnings of €-32.01 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Consumer Packaged Goods company?
A good Retained Earnings depends on the Consumer Packaged Goods industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on InnoCan Pharma and its competitors. InnoCan Pharma's current Retained Earnings is €-32.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCan Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCan Pharma (FRA:IP40) is currently considered Possible Value Trap. The stock's GF Value™ is €8.36, compared to a current price of €1.92 — trading 77.1% below its estimated fair value. The current Retained Earnings is €-32.01 Mil. InnoCan Pharma's overall GF Score™ is 54/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For InnoCan Pharma (FRA:IP40), the current Retained Earnings is €-32.01 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is InnoCan Pharma (FRA:IP40) Overvalued in 2026?

Based on GuruFocus' analysis, InnoCan Pharma stock appears to be undervalued. The current stock price of €1.92 is trading 77.1% below its estimated GF Value™ of €8.36. GuruFocus considers InnoCan Pharma to be Possible Value Trap.

Key valuation signals for FRA:IP40:

  • Retained Earnings: €-32.01 Mil
  • GF Value™: €8.36 vs. price of €1.92 (77.1% below fair value)
  • GF Score™: 54/100 with 2 warning signs

No single metric tells the full story. See the FRA:IP40 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


InnoCan Pharma Business Description

Address 1015, 926 - 5 Avenue SW, Calgary, AB, CAN, T2P 0N7
InnoCan Pharma Corp develops consumer wellness and pharmaceutical products. It has developed a preclinical-stage Cannabidiol-loaded Liposome injection Platform (CBD-LPT) for non-opioid pain management, and is involved in developing and marketing various self-care and CBD beauty products. Additionally, the Group offers cosmetic products such as anti-aging beauty sleeping masks, anti-puffiness eye serum, anti-aging facial serum, hair cream, etc., which are sold mainly through online marketplaces. Its operating segments are: Online sales and Other operations. The majority of its revenue is generated from the Online sales segment, which engages in the development, manufacture, and marketing of cosmetic products. Geographically, the Group generates maximum revenue from the United States.
54GF Score

Get the complete analysis for FRA:IP40

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.92
Price
€8.36
GF Value